Antibodies Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afr

Antibodies Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global antibody contract manufacturing market is expected to witness substantial growth over the next decade, reaching an estimated value of $13.6 billion by 2031, up from $6.3 billion in 2024. This impressive expansion is propelled by a compound annual growth rate (CAGR) of 11.6%, according to a recent report by Fairfield Market Research.

Market Overview and Growth Drivers

Valued at $4.8 billion in 2022, the antibody contract manufacturing market has experienced steady growth fueled by the rising demand for biopharmaceuticals. From 2016 to 2022, the market recorded a historic CAGR of 9.6%. This upward trajectory is set to continue, driven by the increasing prevalence of chronic and infectious diseases and advancements in biotechnology.

Monoclonal Antibodies at the Forefront

Monoclonal antibodies (mAbs) are expected to lead the market, with projections indicating a market value of approximately $15.9 billion by 2033. Renowned for their specificity and effectiveness in treating various diseases, including cancer and autoimmune disorders, mAbs are a cornerstone of the biopharmaceutical industry. Their production process is standardized, ensuring consistency and quality, making them a popular choice for contract manufacturing.

Advancements in Continuous Manufacturing

A key trend influencing the market is the adoption of end-to-end continuous manufacturing processes. This innovative approach promises to transform biologics production by reducing manufacturing time, cutting costs, and minimizing contamination risks. Continuous production methods are becoming increasingly popular, with real-time quality monitoring ensuring high reliability in the final products. Although initial investments are high, the long-term benefits of continuous manufacturing are substantial.

Regional Insights

United States: Innovation Leader

The U.S. dominated the North American market, holding about 89.4% of the market share in 2022. The country's advanced healthcare infrastructure, robust pipeline of clinical trials, and strong government support for biologics drive market growth. The rapid development and approval of antibody drugs, especially during the COVID-19 pandemic, have further strengthened the market.

United Kingdom: R&D Powerhouse

The U.K. accounted for around 26.7% of the European market in 2022, bolstered by significant investments in research and development for infectious diseases. A strong regulatory framework and public sector funding are key factors supporting market growth. The U.K. remains pivotal in global efforts to combat neglected and infectious diseases through innovative antibody therapies.

South Korea: Emerging Leader

South Korea emerged as a significant player in the East Asian market, capturing approximately 70.6% of the market share in 2022. The country's commitment to biopharmaceutical manufacturing excellence, highlighted by events like the Biologics Manufacturing Korea conference, positions it as a key hub for antibody contract manufacturing. Recognitions such as the Korea Bioprocessing Excellence Award underscore South Korea's capabilities in this sector.

Market Segmentation

Product and Expression Systems

Monoclonal antibodies dominated the product segment, holding approximately 89.1% of the market share in 2022. The mammalian expression system, preferred for its ability to produce complex proteins with human-like post-translational modifications, accounted for about 84.4% of the market.

Company Size and Scale of Operations

Mid-sized companies represented around 46.2% of the market in 2022. These companies are increasingly driving innovation and securing approvals for new drugs, despite often lacking in-house manufacturing capabilities. Commercial scale operations held a 54.4% share, driven by the high incidence of chronic diseases and the growing need for contract manufacturing to meet global demand.

Competitive Landscape

The antibody contract manufacturing market is marked by significant consolidation, with major players pursuing mergers and acquisitions to enhance their capabilities. Notable developments include:
• AMRI's Acquisition: In June 2017, AMRI was acquired in a deal valued at over $920 million, reflecting the active M&A market for contract manufacturers.
• AGC Biologics and Ono Pharmaceutical Partnership: In August 2020, AGC Biologics partnered with Ono Pharmaceutical Co., Ltd. to develop innovative biopharmaceuticals, showcasing the industry's collaborative efforts to advance drug development.

Key Market Players Include
• AMRI
• AGC Biologics
• Aldevron
• Eurofins CDMO
• Boehringer Ingelheim BioXcellence
• FUJIFILM Diosynth Biotechnologies
• Emergent BioSolutions
• KBI Biopharma
• Lonza
• Novasep
• Nitto Avecia Pharma Services
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific
• AbbVie, Inc.

Global Antibodies Contract Manufacturing Market Segmentation

By Product:
• Monoclonal Antibodies
• Antibody Fragments
• Polyclonal Antibodies

By Expression System:
• Mammalian
• Microbial

o Bacteria

o Yeast

By Company Size:
• Small
• Mid-sized
• Large
• Very large

By Scale of Operation:
• Preclinical
• Clinical
• Commercial

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.